Lundbeck hunts for new success drugs in niche diseases

Following a large reorganization of Lundbeck's R&D department, Lundbeck is ready to lift the veil on its future focus areas.

Lundbeck EVP and Head of R&D Johan Luthmann | Photo: PR / Lundbeck

The industry has seen it coming for some time, but in its most recent fiscal report, Lundbeck establishes: The Danish pharmaceutical company will be targeting niches in neurology and psychiatry going forward.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs